Pfizer to Work Together with Senator Bob Dole in Men's Health Initiative

Dec 11, 1998, 00:00 ET from Pfizer Inc

    NEW YORK, Dec. 11 /PRNewswire/ -- Pfizer Inc (NYSE:   PFE) announced today
 that former Senate Majority Leader Bob Dole is participating with Pfizer in an
 educational initiative designed to increase awareness of men's health issues.
     A prostate cancer survivor, Senator Dole has been an outspoken advocate
 for screening and early detection of prostate cancer and other serious medical
 conditions affecting American men.
     "One of the most important public health issues facing this country is
 encouraging men to see their doctors," said Senator Dole.  "For example,
 diagnosis of erectile dysfunction can help identify underlying diseases like
 diabetes, hypertension and cardiovascular disease.  I'm convinced this
 campaign can help promote a dialogue between doctors and patients and help men
 pay attention to health problems they might otherwise be afraid to discuss."
     "We are extremely pleased that Senator Dole has made men's health issues a
 priority for 1999," said Pfizer chairman and chief executive officer William
 C. Steere, Jr.  "Senator Dole has shown unparalleled leadership in advocating
 for Americans with disabilities.  We believe that Senator Dole will help make
 men and their partners understand that erectile dysfunction is a medical
 condition, not a source of embarrassment."
     Senator Dole received the "Man of the Year" award from the American
 Foundation for Urologic Disease last night in Washington.
     Senator Dole, a former presidential candidate, has agreed to participate
 in a series of public service activities, including speaking engagements and
 educational advertising that will focus on the importance of patients and
 physicians speaking openly about health issues, including erectile
     Pfizer Inc is a research-based pharmaceutical company with global
 operations.  In 1997 the company reported sales of more than $11 billion and,
 in 1998, anticipates investing approximately $2.2 billion in research and

SOURCE Pfizer Inc